Welcome to our dedicated page for Frontage Hldgs news (Ticker: FTHCY), a resource for investors and traders seeking the latest updates and insights on Frontage Hldgs stock.
Frontage Holdings Corp (FTHCY) is a global contract research organization (CRO) providing integrated drug development services to biopharmaceutical innovators. This page serves as the definitive source for official company announcements, regulatory updates, and strategic developments.
Investors and industry professionals will find curated press releases covering clinical trial milestones, partnership agreements, financial results, and operational expansions. Our aggregation ensures efficient tracking of Frontage’s progress in analytical testing, preclinical research, and global regulatory compliance initiatives.
Key updates are organized for quick scanning, including:
• Clinical trial advancements
• Strategic collaborations
• Regulatory submission milestones
• Operational capacity expansions
Bookmark this page for streamlined access to Frontage’s latest developments in pharmaceutical research services. Check regularly for real-time updates on initiatives impacting drug development timelines and clinical research outcomes.
Frontage Laboratories has acquired Frontage Clinical Services, enhancing its capabilities in Phase I-IIa clinical studies. This strategic move, announced on August 2, 2022, allows Frontage to broaden its service offerings, speeding up the expansion into early phase clinical trials and late phase patient studies. The integration is expected to improve efficiency and mitigate risks for clients' drug development programs. With over 25 years of experience, Frontage Clinical aims to distinguish itself in the CRO sector by responding to evolving client needs.
Frontage Laboratories has achieved a significant milestone with its new toxicology facility in Suzhou, China, receiving an "Experimental Animal Use License" from Jiangsu's Provincial Department of Science and Technology on January 21, 2022. The facility, covering 200,000 square feet, will conduct GLP and non-GLP toxicology and drug metabolism studies. Frontage plans to initiate validation studies of drug safety by Q2 2022 and expects to offer non-GLP studies soon. This facility, alongside others in Chicago and Ohio, will enhance Frontage's capabilities in supporting drug development programs.
Frontage Laboratories has acquired Experimur LLC and its affiliate, Experimur Properties LLC, enhancing its toxicology and non-clinical development services. This strategic acquisition aims to support the pharmaceutical and biotechnology industries with new capabilities in IND and NDA-enabling toxicology studies. Frontage's President, Glenn Washer, emphasized the expanded service range, while CEO Song Li noted the significance of Experimur's expertise in pre-clinical toxicology to Frontage's growth trajectory. Experimur's advanced facility and customer-focused culture align with Frontage's commitment to quality and scientific integrity.
Frontage Laboratories has been recognized as a PanaBIOS Trusted Travel Approved COVID-19 Laboratory Testing Provider by the Africa CDC. This authorization supports the African Union's Saving Lives, Economies, and Livelihoods campaign, aiming to facilitate travel while controlling COVID-19 spread across Africa. Frontage offers RT-PCR, IgM, and IgG testing with same-day results, assisting countless travelers. Their commitment emphasizes scientific expertise in providing vital testing solutions, enhancing travel safety during the pandemic.
On September 8, 2021, Frontage Shanghai announced its acquisition of a 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. This strategic move aims to enhance Frontage's early drug discovery services, leveraging Heyan Biotech's expertise in pharmacodynamic screening and biological assay development. Heyan Biotech collaborates closely with various drug companies and academic institutions, offering technologies that will complement Frontage's existing services. The acquisition positions Frontage to expand its service capacity, particularly in areas like neuropathy, cancer, and metabolic diseases.
Frontage Laboratories has completed a new 71,000 sq. ft. laboratory in Exton, Pennsylvania, designed to meet rising client demands in CMC and Biologics services. The facility expands analytical capabilities, increasing capacity by 50% for pharmaceutical analysis, as well as housing new Central Laboratory Services. President Glenn Washer emphasized the facility's role in enhancing client support and creating shareholder value. This investment reflects Frontage's commitment to providing optimal services to biopharmaceutical companies and ensuring operational efficiency.
Frontage Holdings Corporation (1521.HK) announced a definitive agreement to acquire Quintara Discovery, Inc. via its subsidiary, Frontage Laboratories, Inc.. This acquisition aims to enhance Frontage's drug discovery services by leveraging Quintara's expertise in discovery and ADME profiling. The deal is expected to close in Q3 2021, pending customary conditions. Financing will be through internal resources, aiming to expand Frontage's footprint in the San Francisco/Bay Area and strengthen its reputation as a leading Contract Research Organization.
